Grifols S.A. ADR Stock
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | 0.670% | 0.667% | 2.027% | 14.394% | 8.633% | 1.342% | -50.942% |
| Beximco Pharmaceuticals Ltd. GDR | 2.130% | 5.727% | 6.667% | 15.942% | 15.385% | -20.661% | -42.857% |
| SELLAS Life Sciences Group Inc | 3.130% | 15.600% | 35.257% | 112.761% | 84.272% | -27.265% | -74.884% |
| Eledon Pharmaceuticals Inc. | 13.850% | 11.278% | -1.333% | -65.899% | -63.725% | -33.929% | -90.976% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat